Hyun Cheol Chung | Charles Explorer

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 | Publikace bez příslušnosti k fakultě